Opko acquires Aquashunt maker

Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.

Aquashunt is an implantable device designed to reduce intraocular pressure physiologically. Currently in the preclinical stage, in vivo studies are anticipated to commence towards the end of the year.

"We believe the acquisition of Vidus Ocular is an excellent strategic fit with our ophthalmics business, providing us with the potential to market an innovative product that addresses a serious disease affecting millions of people," said Dr Naveed Shams, Chief Medical Officer and Senior Vice President of Research and Development of OPKO.